Medical and Dental Consultantsí Association of Nigeria
Home - About us - Editorial board - Search - Ahead of print - Current issue - Archives - Submit article - Instructions - Subscribe - Advertise - Contacts - Login 
  Users Online: 734   Home Print this page Email this page Small font sizeDefault font sizeIncrease font size
Year : 2019  |  Volume : 22  |  Issue : 3  |  Page : 386-392

A promising biomarker to distinguish benign and malignant renal tumors: ELABELA

1 Department of Pathology, Firat University, School of Medicine, Elazig, Turkey
2 Department of Histology and Embriology, Firat University, School of Medicine, Elazig, Turkey
3 Department of Internal Medicine and Division of Endocrinology and Metabolism, Firat University, School of Medicine, Elazig, Turkey
4 Department of Biochemistry, Firat University, School of Medicine, Elazig, Turkey
5 Department of Radiology, Firat University, School of Medicine, Elazig, Turkey
6 Department of Oncology, Dokuz Eylül University, School of Medicine, İzmir, Turkey

Correspondence Address:
Dr. G Artas
Firat Üniversitesi Hastanesi, Patoloji Kliniği, 23119, Elâzığ
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/njcp.njcp_105_18

Rights and Permissions

Aim: The aim of this study was to investigate ELABELA (ELA) expression in benign and malignant renal tissues and expression differences in different nuclear grades of clear cell carcinomas. Materials and Methods: Patients that underwent surgery due to renal masses between the years of 2007 and 2017 were used. Control renal tissues (n = 23), papillary RCC (n = 23), clear cell RCC (CcRCC) [Fuhrman Grade1 (n = 23), Fuhrman Grade2 (n = 23), Fuhrman Grade3 (n = 23), Fuhrman Grade4 (n = 23)], and chromophobe RCC (n = 23) were included to the study. The Independent samples t-test was used for 2-point intergroup assessments and the one-way analysis of variance and posthoctukey test was used for the others. Values of P < 0.05 were considered statistically significant. Results: ELA immunoreactivity was observed in proximal and distal tubules in the kidney, but not in glomeruli in control tissues. When compared with control kidney tissue, a statistically significant increase was observed in ELA immunoreactivity in renal oncocytoma. In the chromophobe RCC, ELA immunoreactivity was significantly lower than control kidney tissue, whereas papillary RCC did not show ELA immunoreactivity. However, compared with control kidney tissue, ELA immunoreactivity was not observed in Fuhrman Grade 1 and Grade 2 CcRCC. Also, there was a significant decrease at Fuhrman Grade 3 and Grade 4 CcRCC compared with control kidney tissues. In the statistical analysis of ELA immunoreactivity among the Fuhrman nuclear grades of CcRCCs, The ELA immunoreactivity was higher at Grade 4 CcRCC than Grade 1, Grade 2, and Grade 3. Conclusion: ELA is a usefull molecule to differentiate benign and malign renal tumors. But further broad and comprehensive studies are needed to investigate cellular and molecular mechanisms of ELAs on malign transformation.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded78    
    Comments [Add]    

Recommend this journal